These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 22424434)

  • 1. Biomarkers in inflammatory bowel disease: current practices and recent advances.
    Iskandar HN; Ciorba MA
    Transl Res; 2012 Apr; 159(4):313-25. PubMed ID: 22424434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
    Iijima H; Shinzaki S; Tsujii M; Takehara T
    Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease.
    Kim BG; Kim YS; Kim JS; Jung HC; Song IS
    Dis Colon Rectum; 2002 Aug; 45(8):1062-9. PubMed ID: 12195191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.
    Bennike T; Birkelund S; Stensballe A; Andersen V
    World J Gastroenterol; 2014 Mar; 20(12):3231-44. PubMed ID: 24696607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
    Iborra M; Beltrán B; Nos P
    Gastrointest Endosc Clin N Am; 2016 Oct; 26(4):641-56. PubMed ID: 27633593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Modalities for Inflammatory Bowel Disease: Serologic Markers and Endoscopy.
    Clark C; Turner J
    Surg Clin North Am; 2015 Dec; 95(6):1123-41, v. PubMed ID: 26596918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.
    Lewis JD
    Gastroenterology; 2011 May; 140(6):1817-1826.e2. PubMed ID: 21530748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
    Dulai PS; Peyrin-Biroulet L; Danese S; Sands BE; Dignass A; Turner D; Mantzaris G; Schölmerich J; Mary JY; Reinisch W; Sandborn WJ
    Gastroenterology; 2019 Oct; 157(4):1032-1043.e1. PubMed ID: 31228441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in clinical laboratory tests for inflammatory bowel disease.
    Nakamura RM; Matsutani M; Barry M
    Clin Chim Acta; 2003 Sep; 335(1-2):9-20. PubMed ID: 12927679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
    Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
    Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG; Gomollon F
    Inflamm Bowel Dis; 2009 Nov; 15(11):1746-54. PubMed ID: 19363798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic insights on the metabolism in inflammatory bowel disease.
    Pisani LF; Moriggi M; Gelfi C; Vecchi M; Pastorelli L
    World J Gastroenterol; 2020 Feb; 26(7):696-705. PubMed ID: 32116417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New proteomic approaches for biomarker discovery in inflammatory bowel disease.
    Roda G; Caponi A; Benevento M; Nanni P; Mezzanotte L; Belluzzi A; Mayer L; Roda A
    Inflamm Bowel Dis; 2010 Jul; 16(7):1239-46. PubMed ID: 20127998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission.
    Falvey JD; Hoskin T; Meijer B; Ashcroft A; Walmsley R; Day AS; Gearry RB
    Inflamm Bowel Dis; 2015 Apr; 21(4):824-31. PubMed ID: 25738372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
    Quinton JF; Sendid B; Reumaux D; Duthilleul P; Cortot A; Grandbastien B; Charrier G; Targan SR; Colombel JF; Poulain D
    Gut; 1998 Jun; 42(6):788-91. PubMed ID: 9691915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologic markers in inflammatory bowel disease (IBD).
    Nakamura RM; Barry M
    MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an Academic Medical Center.
    Gupta A; Derbes C; Sellin J
    Inflamm Bowel Dis; 2005 Oct; 11(10):898-902. PubMed ID: 16189419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children.
    Gupta SK; Fitzgerald JF; Croffie JM; Pfefferkorn MD; Molleston JP; Corkins MR
    Inflamm Bowel Dis; 2004 May; 10(3):240-4. PubMed ID: 15290918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.